Similarly in neuroblastoma, PTPN14 mutations are associated with disease relapse (Schramm et al., 2015), while high levels of FER expression have been detected in breast (high-grade basal/TNBC; Ivanova et al., 2013), clear cell renal cell carcinoma (Wei et al., 2013), and non–small cell lung cancer (Kawakami et al., 2013), where high FER expression predicts poorer survival outcomes. The gene discussed is PTPN14; the disease is clear cell renal carcinoma.